Page last updated: 2024-11-06

bimakalim

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bimakalim: potassium channel activator [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60674
CHEMBL ID12552
SCHEMBL ID231904
MeSH IDM0169353

Synonyms (20)

Synonym
sr-44866
emd-52692
bimakalim
bimakalimum [inn-latin]
bimakalim [inn]
2,2-dimethyl-4-(2-oxo-1(2h)-pyridyl)-2h-1-benzopyran-6-carbonitrile
inchi=1/c17h14n2o2/c1-17(2)10-14(19-8-4-3-5-16(19)20)13-9-12(11-18)6-7-15(13)21-17/h3-10h,1-2h
2h-1-benzopyran-6-carbonitrile, 2,2-dimethyl-4-(2-oxo-1(2h)-pyridinyl)-
2,2-dimethyl-4-(2-oxopyridin-1(2h)-yl)-2h-chromene-6-carbonitrile
2,2-dimethyl-4-(2-oxopyridin-1-yl)chromene-6-carbonitrile
CHEMBL12552
bimakalimum
117545-11-6
unii-4mp5gr4h9l
4mp5gr4h9l ,
SCHEMBL231904
DTXSID40151803
bdbm50474004
FT-0710464
Q27260135

Research Excerpts

Overview

Bimakalim appears to be a potent vasodilating drug that may have an important role in management of patients with compromised LV function.

ExcerptReferenceRelevance
"Bimakalim appears to be a potent vasodilating drug that may have an important role in management of patients with compromised LV function."( Potent hemodynamic effects of bimakalim, a new potassium channel opener, in humans.
Buchner-Moell, D; Lahiri, A; Raftery, E; Senior, R, 1993
)
1.3

Treatment

Bimakalim treatment prior to the onset of a 60 min coronary occlusion increases the tolerance of pig myocardium to ischaemia. Pretreatment with bimkalim restores the response expected in the absence of hypoxia. Glibenclamide blocks the effect of bimKalim or further impairs the response to dobutamine when used alone before long-duration hypoxa.

ExcerptReferenceRelevance
"Bimakalim treatment prior to the onset of a 60 min coronary occlusion increases the tolerance of pig myocardium to ischaemia. "( Effect of bimakalim (EMD 52692), an opener of ATP sensitive potassium channels, on infarct size, coronary blood flow, regional wall function, and oxygen consumption in swine.
Becker, KH; Häusler, G; Lues, I; Rohmann, S; Schelling, P; Soei, LK; Verdouw, PD; Weygandt, H, 1994
)
2.13
"Pretreatment with bimakalim restores the response expected in the absence of hypoxia, and glibenclamide blocks the effect of bimakalim or further impairs the response to dobutamine when used alone before long-duration hypoxia."( Protection of human myocardium in vitro by K(ATP) activation with low concentrations of bimakalim.
Criniti, A; del Monte, F; Ducouret, P; Iwashiro, K; Monti, F; Papalia, U; Picard, S; Puddu, PE; Rouet, R; Ruvolo, G; Tonelli, E, 1999
)
0.85

Dosage Studied

ExcerptRelevanceReference
" There was a dose-dependent increase of erythrocyte flow velocity; diameters of capillaries were dilated following a dosage of 6 and 12 micrograms/kg bw, but constricted following a dosage of 24 micrograms/kg bw."( Potassium channel activation improves blood flow pattern of conscious rats in cutaneous microcirculation.
Hertel, RF, 1992
)
0.28
" The dose-response curves for inhibition of I-KATP at different pHo's were found to coincide when plotted for the unionized concentrations of the drugs."( Effects of pH upon the inhibition by sulphonylurea drugs of ATP-sensitive K+ channels in cardiac muscle.
Findlay, I, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID177044Dose required to reduce mean blood pressure after 2 hr following (po) administration conscious spontaneously hypertensive rat1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID197350Dilator activity expressed as potency for relaxation of Aortic rings precontracted with 25 mM K2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID180022Maximum level of relaxation of aortic rings measured as percentage of basal tension.2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID180023Maximum level of relaxation of tracheal strips measured as percentage of basal tension2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID194139Relaxant potency in rat trachea.1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
6-Substituted benzopyrans as potassium channel activators: synthesis, vasodilator properties, and multivariate analysis.
AID194138Relaxant potency in rat aorta.1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
6-Substituted benzopyrans as potassium channel activators: synthesis, vasodilator properties, and multivariate analysis.
AID232391Ratio of ED30(20h) to ED30(2h) was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID161275Binding affinity towards potassium channel of rat aorta using [3H]15 as radioligand1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers.
AID197351Dilator activity expressed as potency for relaxation of Tracheal strips percontracted with 0.6 uM carbachol2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID177208The compound was tested for 30% reduction in mean arterial blood pressure(MAP)1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thiophene systems. 14. Synthesis and antihypertensive activity of novel 7-(cyclic amido)-6-hydroxythieno[3,2-b]pyrans and related compounds as new potassium channel activators.
AID177042Dose required to reduce blood pressure by 30 mmHg after (po) administration in conscious spontaneously hypertensive rat1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID208992Binding affinity towards Sulfonylurea receptor 2B (SUR2B) in cultured rat aortic smooth muscle cells (SMC)2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID166909Compound measured for hyperpolarization of smooth muscle cells of the rabbit main pulmonary artery at concentration 0.1 uM.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
3-Methyl-2H-1-benzopyran potassium channel activators.
AID165453Drug concentration required to induce half maximal hyperpolarization in rabbit main pulmonary arteries1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
3-Methyl-2H-1-benzopyran potassium channel activators.
AID165454Relaxing effect by measuring inhibition of noradrenaline-induced contractions in rabbit main pulmonary arteries1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
3-Methyl-2H-1-benzopyran potassium channel activators.
AID177043Dose required to reduce mean blood pressure after 20 hr following (po) administration conscious spontaneously hypertensive rat1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID185883Antihypertensive effect after 1 mg/kg (po) administration in conscious spontaneously hypertensive rat (over a time period of 0-210 minutes).1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID174888Difference between the pEC50 values in rat aorta and trachea as an indicator of selectivity2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID228165Vasorelaxant activity expressed as negative logarithm of the concentration causing a 50% inhibition of spontaneous myogenic activity in rat portal vein.1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers.
AID76393Inhibition of spontaneous tone in Guinea pig tracheal spiral strips.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID208988Binding affinity to the sulfonylurea receptor 2A (SUR2A) in purified membranes of rat-heart myocytes2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
6-Sulfonylchromenes as highly potent K(ATP)-channel openers.
AID77612Intrinsic activity measured on Guinea pig tracheal spiral strips.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID159676Relaxing effect determined by measuring inhibition of acetylcholine-induced contractions in pig coronary arteries.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
3-Methyl-2H-1-benzopyran potassium channel activators.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (72)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (4.17)18.7374
1990's52 (72.22)18.2507
2000's16 (22.22)29.6817
2010's1 (1.39)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.40 (24.57)
Research Supply Index4.39 (2.92)
Research Growth Index5.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (6.67%)5.53%
Reviews2 (2.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other68 (90.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]